Advanced

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.

Haas, Sylvia; Bode, Christoph; Norrving, Bo LU and Turpie, Alexander Gg (2014) In Vascular Health and Risk Management 10(Mar 10). p.101-114
Abstract
Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice... (More)
Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice versa, coagulation tests, and management of patients requiring invasive procedures or experiencing bleeding or an ischemic event. This article provides practical recommendations relating to the use of rivaroxaban in patients with nonvalvular atrial fibrillation, based on clinical trial evidence, relevant guidelines, prescribing information, and the authors' clinical experience. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Vascular Health and Risk Management
volume
10
issue
Mar 10
pages
101 - 114
publisher
Dove Press
external identifiers
  • pmid:24648742
  • scopus:84897865132
ISSN
1178-2048
DOI
10.2147/VHRM.S55246
language
English
LU publication?
yes
id
17ac6fe2-4e83-45e4-b9b0-f796ea33d9ed (old id 4382959)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24648742?dopt=Abstract
date added to LUP
2014-04-03 20:30:55
date last changed
2017-10-22 03:27:10
@article{17ac6fe2-4e83-45e4-b9b0-f796ea33d9ed,
  abstract     = {Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice versa, coagulation tests, and management of patients requiring invasive procedures or experiencing bleeding or an ischemic event. This article provides practical recommendations relating to the use of rivaroxaban in patients with nonvalvular atrial fibrillation, based on clinical trial evidence, relevant guidelines, prescribing information, and the authors' clinical experience.},
  author       = {Haas, Sylvia and Bode, Christoph and Norrving, Bo and Turpie, Alexander Gg},
  issn         = {1178-2048},
  language     = {eng},
  number       = {Mar 10},
  pages        = {101--114},
  publisher    = {Dove Press},
  series       = {Vascular Health and Risk Management},
  title        = {Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.},
  url          = {http://dx.doi.org/10.2147/VHRM.S55246},
  volume       = {10},
  year         = {2014},
}